On the contrary, in other IDH-mutant tumors such as gliomas, immunotherapy has not met expectations, despite the demonstrated efficacy in preclinical and clinical studies, probably due to the immunosuppressive microenvironment, resulting in drug resistance [119]. The gene discussed is IDH2; the disease is central nervous system cancer.